Examination of Efficacy and Safety of Baricitinib in RA Patients
Sponsored by Shinshu University
About this trial
Last updated 4 years ago
Study ID
BARI2018
Status
Recruiting
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
20+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 7 years ago
What is this trial about?
The aim of this study is to examine the efficacy and adverse events in the following 3
groups in rheumatoid arthritis patients:
1. Baricitinib treatment for 12 months
2. Biologics treatment for 12 months
3. Tofacitinib treatment for 12 months
What are the participation requirements?
Inclusion Criteria
- RA patients
Exclusion Criteria
- Not RA patients
- RA patients who are allergic to the drugs, refused to do this research, or who are pregnant
Locations
Location
Status
Recruiting